Amgen Osteoporosis Drug Approval Plan Derailed Over Newly Found Heart Safety Risk Signal – TheStreet.com

TheStreet.comAmgen Osteoporosis Drug Approval Plan Derailed Over Newly Found Heart Safety Risk SignalTheStreet.com… the incidence of positively adjudicated cardiovascular serious adverse events as 12 months was 2.5% in the Evenity-treated patients compared to 1.9% in the group of patients treated with alendronate, a generic osteoporosis drug that served as the …Higher rate of heart problems with Amgen osteoporosis drug in trialReutersAmgen’s star PhIII osteoporosis drug romo slammed by surprising cardio risk, a big plus for rival Radius drugEndpoints NewsHigher rate of heart problems with Amgen osteoporosis drug in trial (AMGN, UCB, MRK)Markets Insiderall 5 news articles

Source:: Osteoporosis Feed

      

Last modified: May 21, 2017